|
1) 恩地森一, 監修. 青柳豊, 西口修平, 道堯浩二郎, 編. 肝硬変の成因別実態 2008. 東京: 中外医学社; 2009
|
|
|
|
|
2) 小林健一, 清澤研道, 岡上 武, 編. 肝硬変の成因別実態 1998. 東京: 中外医学社; 1999
|
|
|
|
|
|
3) Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97: 2614-8
|
|
|
|
|
4) Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis. 2004; 24: 89-97
|
|
|
|
|
|
5) Rousselet MC, Michalak S, Dupré F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005; 41: 257-64
|
|
|
|
|
|
6) Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357: 1069-75
|
|
|
|
|
|
7) Forns X, Ampurdanés S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36: 986-2
|
|
|
|
|
|
8) Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38: 518-26
|
|
|
|
|
|
9) Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43: 1317-25
|
|
|
|
|
|
10) Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007; 45: 297-306
|
|
|
|
|
|
11) Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343-50
|
|
|
|
|
|
12) Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006; 44: 686-93
|
|
|
|
|
|
13) Sebastiani G, Halfon P, Castéra L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009; 49: 1821-7
|
|
|
|
|
|
14) Castéra L, Sebastiani G, Le Bail B, et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010; 52: 191-8
|
|
|
|
|
|
15) Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41: 48-54
|
|
|
|
|
|
16) Castéra L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009; 50: 59-68
|
|
|
|
|
|
17) Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134: 960-74
|
|
|
|
|
|
18) Vergniol J, Foucher J, Castéra L, et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat. 2009; 16: 132-40
|
|
|
|
|
|
19) Ogawa E, Furusyo N, Toyoda K, et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009; 83: 127-34
|
|
|
|
|
|
20) Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007; 45: 1290-7
|
|
|
|
|
|
21) Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009; 49: 1954-61
|
|
|
|
|
|
22) Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology. 2010; 51: 828-35
|
|
|
|
|
|
23) Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008; 48: 1718-23
|
|
|
|
|
|
24) Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010; 52: 206-10
|
|
|
|
|
|
25) Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008; 47: 380-4
|
|
|
|
|
|
26) Sagir A, Erhardt A, Schmitt M, et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008; 47: 592-5
|
|
|
|
|
|
27) Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009; 252: 595-604
|
|
|
|
|
|
28) Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009; 18: 303-10
|
|
|
|
|
|
29) Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010; 30: 538-45
|
|
|
|
|
|
30) Yoneda M, Suzuki K, Kato S, et al. Nonalcoholic Fatty Liver Disease: US-based Acoustic Radiation Force Impulse Elastography. Radiology. 2010 Jun 7. [Epub ahead of print]
|
|
|
|
|
|
31) Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001; 357: 196-7
|
|
|
|
|
|
32) Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002; 123: 483-91
|
|
|
|
|
|
33) Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004; 35: 107-12
|
|
|
|
|
|
34) Miyake Y, Ando M, Kaji E, et al. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 2008; 38: 980-6
|
|
|
|
|
35) Akahoshi T, Tomikawa M, Korenaga D, et al. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc. 2010; 24: 680-5
|
|
|
|
|
|
36) Morihara D, Kobayashi M, Ikeda K, et al. Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res. 2009; 39: 439-47
|
|
|
|
|
|
37) Tomikawa M, Akahoshi T, Sugimachi K, et al. Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J Gastroenterol Hepatol. 2010; 25: 397-402
|
|
|
|
|
|
38) Amin MA, el-Gendy MM, Dawoud IE, et al. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg. 2009; 33: 1702-10
|
|
|
|
|
|
39) Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359: 2429-41
|
|
|
|
|
|
40) Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 May 14. [Epub ahead of print]
|
|
|
|
|
|
41) Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8: 192-9
|
|
|
|
|
|
42) Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010; 138: 493-502
|
|
|
|
|
|
43) Schiff E, Simsek H, Lee WM, et al. Effcacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008; 103: 2776-83
|
|
|
|
|
|
44) Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52: 176-82
|
|
|
|
|
|
45) Cohen SM, Levy RM, Jovanovich JF, et al. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009; 43: 1008-10
|
|
|
|
|
|
46) Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50: 2001-6
|
|
|
|
|
|
47) Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2009; 16: 265-71
|
|
|
|
|
|
48) Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology. 2010 Jun 14. [Epub ahead of print]
|
|
|
|
|
|
49) Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49: 2087-107
|
|
|
|
|
|
50) Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int. 2009; 29: 415-9
|
|
|
|
|
|
51) Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut. 2007; 56: 597-9
|
|
|
|
|
|
52) Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990; 12: 716-24
|
|
|
|
|
|
53) Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology. 2006; 44: 1535-42
|
|
|
|
|
|
54) Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130: 1652-60
|
|
|
|
|
|
55) Huo TI, Wang YW, Yang YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. 2007; 27: 498-506
|
|
|
|
|
|
56) Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007; 13: 1174-80
|
|
|
|
|
|
57) Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008; 48: 204-13
|
|
|
|
|
|
58) Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010; 53: 283-90
|
|
|
|
|
|
59) Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the effcacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010 Apr 13. [Epub ahead of print]
|
|
|
|
|